Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 14/20 | 0.42 |
| ▸ | NPY1R | P25929 | 8/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.42 |
| ▸ | NPY2R | P49146 | 5/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29655812 | 1.00 | PTGS1 (0.44) | PTGS1GSTK1NPY4RNPY1RNPY5R | |
| SCHEMBL29655852 | 1.00 | PTGS1 (0.44) | PTGS1GSTK1NPY4RNPY1RNPY5R | |
| SCHEMBL29655840 | 1.00 | PTGS1 (0.44) | PTGS1GSTK1NPY4RNPY1RNPY5R | |
| SCHEMBL29655791 | 1.00 | PTGS1 (0.44) | PTGS1GSTK1NPY4RNPY1RNPY5R | |
| SCHEMBL29590332 | 0.98 | PTGS1 (0.43) | PTGS1GSTK1NPY4RNPY1RNPY5R | |
| SCHEMBL19791172 | 0.95 | PTGS1 (0.41) | PTGS1GSTK1NPY4RNPY1RNPY5R | |
| SCHEMBL30254242 | 0.94 | GNAI3 (0.43) | PTGS1GSTK1NPY4RNPY1RNPY5R | |
| SCHEMBL7306618 | 0.93 | PTGS1 (0.43) | PTGS1GSTK1NPY4RNPY1RNPY5R | |
| SCHEMBL29630413 | 0.93 | PTGS1 (0.43) | PTGS1GSTK1NPY4RNPY1RNPY5R | |
| SCHEMBL31691755 | 0.92 | NPY4R (0.44) | PTGS1GSTK1NPY4RNPY1RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | claimed |
| EP-3704143-B1 | CHEMO-ENZYMATIC SYNTHESIS OF LIRAGLUTIDE, SEMAGLUTIDE AND GLP-1 | FRESENIUS KABI IPSUM S R L (IT) | 2023-10-18 | — | — | EP | claimed |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | ENZENE BIOSCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | disclosed |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | disclosed |
| WO-2025093774-A1 | GLUCAGON-LIKE PEPTIDE 1 AGONISTS | Constructive Biology Limited (GB) | 2025-05-08 | — | — | WO | disclosed |
| US-20250074964-A1 | STABLE GLP-1 ANALOGS FOR THE TREATMENT OF HUMAN DISEASE AND DISORDERS | Ambio, Inc. | 2025-03-06 | — | — | US | disclosed |
| CN-116120427-B | Semex lattice Synthesis method of lupeptide | 浙江九洲药业股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024159569-A1 | METHOD FOR SYNTHESIZING SEMAGLUTIDE | 浙江九洲药业股份有限公司 | 2024-08-08 | — | — | WO | disclosed |
| US-20240150423-A1 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | Nanjing Finepeptide Biopharmaceutical Co.,Ltd (CN) | 2024-05-09 | — | — | US | disclosed |
| WO-2024068827-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2024-04-04 | — | — | WO | disclosed |
| CN-117402256-A | Protein dimers consisting of GLP-1 and EGF (A) analogues | 乐普（北京）医疗器械股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117202936-A | Glucagon-like peptide compounds | 诺华股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-116120427-A | Synthesis method of semaglutin | 浙江九洲药业股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023012709-A1 | AN IMPROVED PROCESS FOR FMOC SYNTHESIS OF SEMAGLUTIDE | USV PRIVATE LIMITED (IN) | 2023-02-09 | — | — | WO | disclosed |
| US-20220153804-A1 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | ENZENE BIOSCIENCES LIMITED (IN) | 2022-05-19 | — | — | US | disclosed |
| CN-110818775-B | Protein and polypeptide protective agent and application thereof | 北京双鹭药业股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150423-A1 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | GLP1R, IAPP, GCG | PTGS1 732/4885GSTK1 632/4885NPY4R 77/4885 |
| US-20220153804-A1 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | GLP1R, GIPR, GCGR | PTGS1 2797/4885GSTK1 4387/4885NPY4R 14/4885 |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | GLP1R, GIPR, GCG | PTGS1 4230/4885GSTK1 3704/4885NPY4R 43/4885 |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GCG | PTGS1 3170/4885GSTK1 2586/4885NPY4R 52/4885 |
| US-20250074964-A1 | STABLE GLP-1 ANALOGS FOR THE TREATMENT OF HUMAN DISEASE AND DISORDERS | GLP1R, GIPR, GPR119 | PTGS1 3684/4885GSTK1 2195/4885NPY4R 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.